Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE2.3000
- TODAY'S CHANGE (%)0.1700 (7.9812%)
- Bid / Lots2.2500/ 4
- Ask / Lots2.4800/ 2
- Open / Previous Close2.1400 / 2.1300
- Day Range
- 52 Week Range
- Volume79,995
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 412 | 2.08 |
| 09:34 ET | 100 | 2.19 |
| 09:41 ET | 100 | 2.12 |
| 09:45 ET | 100 | 2.12 |
| 09:50 ET | 100 | 2.13 |
| 09:52 ET | 600 | 2.15 |
| 09:59 ET | 500 | 2.142 |
| 10:01 ET | 100 | 2.16 |
| 10:03 ET | 500 | 2.1262 |
| 10:08 ET | 100 | 2.12 |
| 10:10 ET | 100 | 2.15 |
| 10:14 ET | 565 | 2.1201 |
| 10:21 ET | 100 | 2.155 |
| 10:26 ET | 100 | 2.135 |
| 10:30 ET | 1006 | 2.175 |
| 10:44 ET | 100 | 2.17 |
| 10:46 ET | 600 | 2.21 |
| 10:51 ET | 1331 | 2.2001 |
| 10:55 ET | 500 | 2.225 |
| 10:57 ET | 100 | 2.225 |
| 11:00 ET | 300 | 2.2265 |
| 11:02 ET | 1878 | 2.2899 |
| 11:09 ET | 2100 | 2.21 |
| 11:11 ET | 100 | 2.21 |
| 11:13 ET | 500 | 2.25 |
| 11:27 ET | 200 | 2.255 |
| 11:29 ET | 100 | 2.25 |
| 11:38 ET | 143 | 2.2845 |
| 11:40 ET | 1426 | 2.2217 |
| 11:42 ET | 897 | 2.19 |
| 11:44 ET | 1691 | 2.1844 |
| 11:45 ET | 1700 | 2.21 |
| 11:47 ET | 2500 | 2.2142 |
| 11:56 ET | 2100 | 2.21 |
| 12:09 ET | 500 | 2.23 |
| 12:20 ET | 500 | 2.245 |
| 12:21 ET | 700 | 2.27 |
| 12:23 ET | 19110 | 2.27 |
| 12:27 ET | 1673 | 2.31 |
| 12:30 ET | 1400 | 2.3 |
| 12:39 ET | 800 | 2.3 |
| 12:41 ET | 1850 | 2.33 |
| 12:43 ET | 569 | 2.35 |
| 12:48 ET | 100 | 2.29 |
| 12:57 ET | 100 | 2.31 |
| 01:01 ET | 200 | 2.28 |
| 01:06 ET | 100 | 2.26 |
| 01:10 ET | 100 | 2.26 |
| 01:12 ET | 100 | 2.26 |
| 01:15 ET | 600 | 2.295 |
| 01:26 ET | 100 | 2.295 |
| 01:35 ET | 1300 | 2.32 |
| 01:42 ET | 1000 | 2.3299 |
| 01:50 ET | 300 | 2.31 |
| 01:51 ET | 100 | 2.32 |
| 02:00 ET | 100 | 2.3 |
| 02:02 ET | 2200 | 2.3105 |
| 02:04 ET | 300 | 2.3 |
| 02:06 ET | 100 | 2.315 |
| 02:08 ET | 6500 | 2.32 |
| 02:09 ET | 700 | 2.32 |
| 02:11 ET | 347 | 2.305 |
| 02:31 ET | 100 | 2.28 |
| 02:33 ET | 100 | 2.305 |
| 02:36 ET | 100 | 2.3108 |
| 02:40 ET | 100 | 2.28 |
| 02:42 ET | 100 | 2.3 |
| 02:44 ET | 100 | 2.305 |
| 02:47 ET | 100 | 2.27 |
| 02:49 ET | 100 | 2.3 |
| 02:51 ET | 2100 | 2.295 |
| 02:58 ET | 100 | 2.26 |
| 03:02 ET | 200 | 2.295 |
| 03:03 ET | 300 | 2.2633 |
| 03:05 ET | 100 | 2.26 |
| 03:12 ET | 400 | 2.26 |
| 03:16 ET | 100 | 2.26 |
| 03:20 ET | 100 | 2.26 |
| 03:23 ET | 300 | 2.26 |
| 03:25 ET | 300 | 2.295 |
| 03:30 ET | 300 | 2.26 |
| 03:32 ET | 100 | 2.295 |
| 03:39 ET | 2000 | 2.3 |
| 03:43 ET | 100 | 2.3 |
| 03:50 ET | 100 | 2.3153 |
| 03:56 ET | 200 | 2.32 |
| 03:57 ET | 1131 | 2.32 |
| 03:59 ET | 500 | 2.3 |
Apr 18, 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States, from 9:32AM ET on Thursday Apr 18, 2024 by Dow Jones
9:32AM ET on Thursday Apr 18, 2024 by Dow JonesImmix Biopharma on Track to Dose NXC-201 Patients in United States, from 9:32AM ET on Thursday Apr 18, 2024 by Dow Jones
9:32AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 15, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 56.2M | -2.6x | --- |
Reneo Pharmaceuticals Inc | 56.5M | -0.7x | --- |
OKYO Pharma Ltd | 45.9M | -0.1x | --- |
Oncolytics Biotech Inc | 80.4M | -3.5x | --- |
AVROBIO Inc | 53.8M | 4.4x | --- |
Intensity Therapeutics Inc | 53.5M | -4.7x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $56.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 26.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.88 |
Book Value | $0.82 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
